BRAF and melanoma: Although both BRAF V600E and V600K mutant melanoma benefit from BRAFi, melanomas with BRAF V600K mutations have shorter progression-free survival under BRAF inhibitors but superior response to immune checkpoint inhibitors compared to V600E mutants [10,14,15,18,86].